Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials

Abstract

Background: To report the cardiovascular and renal effects of incretin-based therapies. Method: The studies of clinical trials on incretin-based therapy published in medical journals from years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions of which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore incretin-based therapies do not adversely affect renal function.

Experimental Agents for the Treatment of Atherosclerosis: New Directions

“… 49 Incretin-based therapies have also been developed and are reported to be effective and well tolerated, leading to lowering the risk of cardiovascular events. 50 …”

Diabetes Mellitus: An Update

“…Kyriakos et al . reviewed clinical trials and concluded that this medication is showed to be effective in lowering the risk of cardiovascular disease without burden the renal function [ 4 ]. In addition, a new group of hypoglycemic drugs has been used to treat diabetes type 2.; the active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors.…”